专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

US20100266497A1 Internalizing Anti-CD74 Antibodies and Methods of Use 有权
标题翻译：内化抗CD74抗体及其使用方法
公开(公告)号：US20100266497A1
公开(公告)日：2010-10-21
申请号：US12794823
申请日：2010-06-07
申请人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00 , C12N5/07 , C12N5/0781 , C12N5/0783 , A61K51/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
摘要翻译：本发明提供人源化，嵌合和人抗CD74抗体，CD74抗体融合蛋白，免疫缀合物，疫苗和结合CD74的双特异性，主要组织相容性复合体（MHC）II类不变链I 1可用于治疗 B细胞病变，B细胞恶性肿瘤，其他细胞与CD74反应的其他恶性肿瘤，以及自身免疫性疾病以及治疗和诊断方法的诊断。

92. 发明申请

US20100196266A1 Humanized Anti-HLA-DR Antibodies 有权
标题翻译：人源化抗HLA-DR抗体
公开(公告)号：US20100196266A1
公开(公告)日：2010-08-05
申请号：US12754140
申请日：2010-04-05
申请人： David M. Goldenberg , Hans J. Hansen , Chien-Hsing Chang
发明人： David M. Goldenberg , Hans J. Hansen , Chien-Hsing Chang
IPC分类号： A61K51/10 , C07K16/30 , C07K19/00 , A61K39/395 , A61K38/19 , A61K38/20 , A61K38/21 , C07H21/04 , A61P35/00 , A61P35/02 , C12N9/96
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.
摘要翻译：本发明涉及使用人源化抗HLA-DR抗体的组合物和方法。在优选的实施方案中，抗体诱导凋亡并抑制淋巴瘤细胞的增殖而不诱导CDC或ADCC。在更优选的实施方案中，人源化抗HLA-DR抗体与鼠L243抗体结合HLA-DR相同的表位或与鼠L243抗体竞争结合HLA-DR。最优选地，人源化抗HLA-DR抗体对亲本鼠抗体的HLA-DR表现出更高的亲和力。人源化HLA-DR抗体可用于治疗各种疾病如癌症，自身免疫疾病或免疫调节功能，并且特别用于治疗B细胞淋巴瘤和白血病。在最优选的实施方案中，人源化抗HLA-DR抗体能够诱导对其它B细胞抗体如利妥昔单抗有抗性的淋巴瘤的至少部分缓解。

93. 发明申请

US20100068136A1 Anti-CD19 Antibodies 有权
标题翻译：抗CD19抗体
公开(公告)号：US20100068136A1
公开(公告)日：2010-03-18
申请号：US12266999
申请日：2008-11-07
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395 , C07K16/00 , A61K51/10 , A61K38/21 , A61K38/20 , A61P37/00 , A61P29/00
CPC分类号： C07K16/2803 , A61K38/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1069 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/2809 , C07K16/283 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3061 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/732 , C07K2317/92
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
摘要翻译：本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。在更具体的实施方案中，人源化抗CD19抗体可以包含设计用于改善蛋白质稳定性，抗体结合和/或表达水平的一个或多个框架区氨基酸取代。在特别优选的实施方案中，所述取代包括hA19 VH序列中的Ser91Phe取代。

94. 发明授权

US07541440B2 Chimeric, human and humanized anti-granulocyte antibodies and methods of use 有权
标题翻译：嵌合，人和人源化抗粒细胞抗体及其使用方法
公开(公告)号：US07541440B2
公开(公告)日：2009-06-02
申请号：US10672278
申请日：2003-09-29
申请人： David M. Goldenberg , Hans J. Hansen , Shui-on Leung
发明人： David M. Goldenberg , Hans J. Hansen , Shui-on Leung
IPC分类号： C12P21/08 , C07K16/00 , C07K17/00 , C07K17/14 , A61K39/00 , A61K39/395
CPC分类号： G01N33/57426 , A61K39/395 , A61K51/10 , A61K51/1027 , C07K16/2803 , C07K2317/24 , C07K2317/567 , C07K2319/00 , G01N2500/00 , A61K2300/00
摘要： The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.
摘要翻译：本发明提供人源化，嵌合和人类MN3抗体，融合蛋白及其片段。抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断粒细胞相关疾病和疾病如白血病。

95. 发明授权

US07534427B2 Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins 有权
标题翻译：免疫治疗B细胞恶性肿瘤和自身免疫疾病使用非共轭抗体和共轭抗体和抗体组合和融合蛋白
公开(公告)号：US07534427B2
公开(公告)日：2009-05-19
申请号：US10747199
申请日：2003-12-30
申请人： David M. Goldenberg , Hans J. Hansen
发明人： David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K39/395 , A61K39/44 , A61K38/19 , C12P21/08 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2896 , A61K51/1018 , A61K51/1045 , A61K51/109 , A61K51/1093 , C07K16/2812 , C07K16/2815 , C07K16/2821 , C07K16/2827 , C07K16/2845 , C07K16/2851 , C07K16/2878 , C07K16/2887 , C07K16/2893
摘要： The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.
摘要翻译：本发明涉及一种治疗和诊断哺乳动物中B细胞相关疾病或T细胞相关疾病或自身免疫性疾病的方法，该方法是通过向哺乳动物同时或依次施用治疗组合物，其包含药学上可接受的载体和至少一种缀合的抗体，其中未进行非放射性标记的抗体的预处理。

96. 发明授权

US07462352B2 Methods of treatng B-cell diseases using humanized anti-CD19 antibodies 有权
标题翻译：使用人源化抗CD19抗体治疗B细胞疾病的方法
公开(公告)号：US07462352B2
公开(公告)日：2008-12-09
申请号：US11445410
申请日：2006-06-01
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K51/00 , A61K49/00 , A61K39/395 , C07K17/00
CPC分类号： C07K16/2803 , A61K2039/507 , C07K16/2887 , C07K2317/565
摘要： The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.
摘要翻译：本发明提供了结合人B细胞标记的人源化，嵌合和人抗CD19抗体，抗-CD19抗体融合蛋白及其片段。此类抗体，融合蛋白及其片段可用于治疗和诊断各种B细胞病症，包括B细胞恶性肿瘤和自身免疫性疾病。

97. 发明申请

US20080241141A1 METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY AND DETECTION OF INFLAMMATORY AND IMMUNE-DYSREGULATORY DISEASE, INFECTIOUS DISEASE, PATHOLOGIC ANGIOGENESIS AND CANCER 审中-公开
公开(公告)号：US20080241141A1
公开(公告)日：2008-10-02
申请号：US11929315
申请日：2007-10-30
申请人： David M. Goldenberg , Hans J. Hansen
发明人： David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K38/02 , A61K39/395 , A61P37/00
CPC分类号： A61K39/3955 , A61K31/513 , A61K38/193 , A61K38/2013 , A61K38/4866 , A61K39/40 , A61K45/06 , A61K49/0002 , A61K2039/505 , A61K2039/507 , C07K16/1203 , C07K16/24 , C07K16/241 , C07K16/248 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/734
摘要： Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include (i) proinflammatory effectors of the innate immune system, (ii) coagulation factors, and (iii) targets specifically associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, wherein the targets included in group (iii) are neither a proinflammatory effector of the immune system nor a coagulation factor. When the multispecific antagonist reacts specifically with a target associated with an inflammatory or immune-dysregulatory disorder, with a pathologic angiogenesis or cancer, or with an infectious disease, it also binds specifically with at least one proinflammatory effector of the immune system or at least one coagulation factor. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system, such as a receptor or antigen of B cells, T cells, neutrophils, monocytes and macrophages, and dendritic cells, a modulator of coagulation, or a proinflammatory cytokine. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system or coagulation factors. Such diseases more particularly include acute and chronic inflammatory disorders, autoimmune diseases, giant cell arteritis, septicemia and septic shock, coagulopathies (including diffuse intravascular coagulation), neuropathies, graft versus host disease, infectious diseases, acute respiratory distress syndrome, granulomatous diseases, transplant rejection, asthma, cachexia, myocardial ischemia, and atherosclerosis. Other diseases also responsive to these therapies include cancers and conditions with pathological angiogenesis.

98. 发明申请

US20080138333A1 INTERNALIZING ANTI-CD74 ANTIBODIES AND METHODS OF USE 有权
公开(公告)号：US20080138333A1
公开(公告)日：2008-06-12
申请号：US11754902
申请日：2007-05-29
申请人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Shui-on Leung , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395 , A61P17/00 , A61P21/00 , A61P31/00 , A61P35/00 , A61K39/00 , A61K38/46 , A61K51/00 , A61K31/70 , A61K45/00 , A61K38/21
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.

99. 发明授权

US07323168B2 Immunotherapy for chronic myelocytic leukemia 有权
标题翻译：免疫治疗慢性骨髓性白血病
公开(公告)号：US07323168B2
公开(公告)日：2008-01-29
申请号：US10853150
申请日：2004-05-26
申请人： David M. Goldenberg , Hans J. Hansen
发明人： David M. Goldenberg , Hans J. Hansen
IPC分类号： A61K39/395
CPC分类号： C07K16/2803
摘要： Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies, such as immunoconjugates or chemotherapeutics. In either format, an effective therapy for treating CML is provided, which avoids the toxic side-effects typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when co-administered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.
摘要翻译：使用裸抗粒细胞抗体的免疫治疗提供治疗慢性骨髓性白血病（CML）的有效手段。这样的抗体可以单独施用或与其它疗法组合施用，例如免疫缀合物或化学治疗剂。以任一格式，提供治疗CML的有效治疗方法，其避免通常与癌症治疗相关的毒副作用。当与诱导表达共同施用时，所公开的免疫治疗也可有效治疗急性髓细胞性白血病（AML），所述诱导剂诱导表达最低限度地显示在原粒细胞表面上。

100. 发明授权

US07300655B2 Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof 有权
标题翻译：甲胎蛋白Immu31抗体和融合蛋白及其使用方法
公开(公告)号：US07300655B2
公开(公告)日：2007-11-27
申请号：US10631722
申请日：2003-08-01
申请人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
发明人： Hans J. Hansen , Zhengxing Qu , David M. Goldenberg
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译：本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式